Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Patent
1993-11-08
1995-06-27
Higel, Floyd D.
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
544360, 544364, 544370, 546193, 546194, 546210, 5483355, 5483401, C07D23364, C07D40104, C07D40106, C07D40304, C07D40306, A61K 31415
Patent
active
054281644
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to certain aminomethyl phenylimidazole derivatives which selectively bind to brain dopamine receptor subtypes. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Furthermore compounds of this invention may be useful in treating the extraparamidyl side effects asssociated with the use of conventional neuroleptic agents. The interaction of aminomethyl phenylimidazole derivatives of the invention with dopamine receptor subtypes is described. This interaction results in the pharmacological activities of these compounds.
2. Description of the Related Art
Schizophrenia or psychosis is a term used to describe a group of illnesses of unknown origin which affect approximately 2.5 million people in the United States. These disorders of the brain are characterised by a variety of symptoms which are classified as positive symptoms (disordered thought, hallucinations and delusions) and negative symptoms (social withdrawal and unresponsiveness). These disorders have an age of onset in adolescence or early adulthood and persist for many years. The disorders tend to become more severe during the patients lifetime and can result in prolonged institutionalization. In the US today, approximately 40% of all hospitalized psychiatric patents suffer from schizophrenia.
During the 1950's physicians demonstrated that they could sucessfully treat psychotic patients with medications called neuroleptics; this classification of antipsychotic medicatin was based largely on the activating (neuroleptic) properties of the nervous system by these drugs. Subsequently, neuroleptic agents were shown to increase the concentrations of dopamine metabolites in the brain suggesting altered neuronal firing of the dopamine system. Additional evidence indicated that dopamine could increase the activity of adenylate cyclase in the corpus striatum, an effect reversed by neuroleptic agents. Thus, cumulative evidence from these and later experiments strongly suggested that the neurotransmitter dopamine was involved in schizophrenia.
One of the major actions of antipsychotic medication is the blockade of dopamine receptors in brain. Several dopamine systems appear to exist in the brain and at least three classes of dopamine receptors appear to mediate the actions of this transmitter. These dopamine receptors differ in their pharmacological specificity and were originally classified upon these differences in the pharmacology of different chemical series. Butyrophenones, containing many potent antipsychotic drugs were quite weak at the dopamine receptor that activated adenylate cyclase (now known as a D1 dopamine receptor). In contrast, they labelled other dopamine receptors (called D2 receptors) in the subnanomolar range and a third type D3 in the nanomolar range. Phenothiazines possess nanomolar affinity for all three types of dopamine receptors. Other drugs have been developed with great specificity for the D1 subtype receptor.
Recently, a new group of drugs (such as sulpiride and clozapine) have been developed with a lesser incidence of extrapyramidal side effects than classical neuroleptics. In addition, there is some indication that they may be more beneficial in treating negative symptoms in some patients. Since all D2 blockers do not possess a similar profile, hypotheses underlying the differences have been investigated. The major differences have been in the anticholinergic actions of the neuroleptics as well as the possilility that the dopamine receptors may differ in motor areas from those in the limbic areas thought to mediate the antipsychotic responses. The existence of the D3 and other as yet undiscovered dopamine receptors may contribute to this profile. Some of the atypical compounds possess similar activity at both D2 and D3 receptors. The examples of thi
REFERENCES:
patent: 2532547 (1950-12-01), Goldberg et al.
patent: 2744899 (1956-05-01), Huebner
patent: 3362956 (1968-01-01), Archer
patent: 3468892 (1969-09-01), Tomcufcik et al.
patent: 3491098 (1970-01-01), Archer
patent: 4329470 (1982-05-01), Grisar et al.
patent: 4357341 (1982-11-01), Fedan et al.
patent: 4404387 (1983-09-01), Gall
patent: 5059601 (1991-10-01), Salimbeni et al.
patent: 5159083 (1992-10-01), Thurkauf et al.
patent: 5248689 (1993-09-01), Girard et al.
patent: 5274095 (1993-12-01), Braun et al.
patent: 5296493 (1994-03-01), Moldt et al.
Ingle and Taylor, J. Pharm. Pharmacol. 15: 620-623 (1963) "Synthesis of some Histamine Derivatives Having Potential Histamine-Like or Antihistamine Activity".
Hutchison Alan J.
Thurkauf Andrew Y.
Higel Floyd D.
Neurogen Corporation
LandOfFree
Certain 4-aryl substituted piperazinyl and piperidinylmethyl phe does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Certain 4-aryl substituted piperazinyl and piperidinylmethyl phe, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain 4-aryl substituted piperazinyl and piperidinylmethyl phe will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-288673